Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Himanshi Diwan"'
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 10, Iss 1, Pp 1-21 (2024)
Abstract Background Sustained drug delivery system (DDS) for clinically relevant osteosarcoma medications is a promising strategy for treatment. β-tricalcium phosphate (β-TCP) microbeads loaded with doxorubicin hydrochloride (DOX) and cis-diammined
Externí odkaz:
https://doaj.org/article/5ac3bd523acf418090f34dde6640f3f7
Publikováno v:
Diagnostic Pathology, Vol 19, Iss 1, Pp 1-5 (2024)
Abstract Melanocytic lesions involving the central nervous system are extremely rare and pose a diagnostic challenge owing melanoma being the third most common malignancy metastasizing to the spine. Morphology and immunohistochemistry are identical i
Externí odkaz:
https://doaj.org/article/c0449e8788004944985c285801014ed0
Autor:
Anurag Mehta, Himanshi Diwan, Shrinidhi Nathany, Ullas Batra, Manoj Gupta, Manoj Kumar Panigrahi, Dushyant Kumar, Sakshi Mattoo, Aayushi Singh
Publikováno v:
Clinical Pathology, Vol 17 (2024)
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners doc
Externí odkaz:
https://doaj.org/article/be6a27af177c40dcb92bcc708e6d85d3
Autor:
Anurag Mehta, Himanshi Diwan, Garima Gupta, Shrinidhi Nathany, Shalini Agnihotri, Surender Dhanda
Publikováno v:
Journal of Pathology and Translational Medicine, Vol 56, Iss 4, Pp 212-216 (2022)
Background Founder mutation is a heritable genetic alteration observed with high frequency in a geographically and culturally isolated population where one or more ancestors becomes the forebearer of the altered gene. The current study reports two fo
Externí odkaz:
https://doaj.org/article/42597e554b174aef9af05ed09d01552d
Publikováno v:
Journal of Pathology and Translational Medicine, Vol 56, Iss 1, Pp 53-56 (2022)
SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non–small cell lung carcinomas. We present
Externí odkaz:
https://doaj.org/article/42ee0f92bae0492ca1e6151b23c66fdc
Autor:
Anurag Mehta, Himanshi Diwan, Diksha Karki, Divya Bansal, Meenakshi Kamboj, Anila Sharma, Shrinidhi Nathany, Sakshi Mattoo, Dushyant Kumar
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 8, Iss , Pp 100205- (2022)
Small Cell Carcinoma of the Ovary-Hypercalcemic Type (SCCOHT) is an aggressive tumor that affects young females, typically in the second decade of life. The patients with SCCOHT harbor somatic or germline mutations in the SMARCA4 gene. Germline mutat
Externí odkaz:
https://doaj.org/article/6a1f6cf61bf3437fbebf26f9dc139f43
Publikováno v:
Journal of Cytology, Vol 34, Iss 4, Pp 217-220 (2017)
Background: Tumors of the central nervous system in the pediatric age group occur relatively frequently during the early years of life. Brain tumors are the most common solid malignancies of childhood and only second to acute childhood leukemia. Squa
Externí odkaz:
https://doaj.org/article/06bb193055024030b8e0371d227223f9
Publikováno v:
Journal of Cytology, Vol 37, Iss 4, Pp 214-215 (2020)
Externí odkaz:
https://doaj.org/article/a6094ce07c274650802314eed823e852
Autor:
Sunil Pasricha, Himanshi Diwan, Divya Bansal, Ankush Jajodia, Mudit Agarwal, Gurudutt Gupta, Anila Sharma, Garima Durga, Meenakshi Kamboj, Venkata Pradeep Babu Koyyala, Anurag Mehta
Publikováno v:
Head Neck Pathol
BACKGROUND: Plasmacytoma involving thyroid gland is infrequent and can present as either primary extramedullary plasmacytoma or secondary to multiple myeloma. METHODS AND RESULTS: We present a case of 71 years old male who complained of a huge anteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9a377f48294e9d2c8457e5d5e467ceb
https://doi.org/10.1007/s12105-022-01465-2
https://doi.org/10.1007/s12105-022-01465-2
Publikováno v:
Journal of Pathology and Translational Medicine
Journal of Pathology and Translational Medicine, Vol 56, Iss 1, Pp 53-56 (2022)
Journal of Pathology and Translational Medicine, Vol 56, Iss 1, Pp 53-56 (2022)
SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non–small cell lung carcinomas. We present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61838e3622b9895db0966b3c3a17238c
https://doi.org/10.4132/jptm.2021.09.16
https://doi.org/10.4132/jptm.2021.09.16